Diego Muñoz-Torrero Selected Research

Amyloid (Amyloid Fibrils)

4/2022	Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis.
3/2021	Clock/Sleep-Dependent Learning and Memory in Male 3xTg-AD Mice at Advanced Disease Stages and Extrinsic Effects of Huprine X and the Novel Multitarget Agent AVCRI104P3.
1/2017	Unveiling a novel transient druggable pocket in BACE-1 through molecular simulations: Conformational analysis and binding mode of multisite inhibitors.
1/2017	Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease.
12/2016	Special Issue: "Molecules against Alzheimer".
3/2016	Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs.
8/2015	Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies.
1/2013	Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diego Muñoz-Torrero Research Topics

Disease

16	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2008
3	Neuroinflammatory Diseases 01/2022 - 08/2015
3	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2016 - 04/2003
2	Prion Diseases (Transmissible Spongiform Encephalopathies) 04/2015 - 01/2012
1	Amnesia (Dissociative Amnesia) 04/2022
1	Inflammation (Inflammations) 09/2018
1	Dementia (Dementias) 09/2018
1	Myasthenia Gravis 03/2018
1	Trypanosomiasis 01/2018
1	Encephalitis (Encephalitis, Rasmussen) 01/2018
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2016
1	Seizures (Absence Seizure) 08/2015
1	Amyloid Plaque 03/2015
1	Dehydration (Water Stress) 04/2006
1	Gliosis 04/2003

Drug/Important Bio-Agent (IBA)

8	Amyloid (Amyloid Fibrils)IBA 04/2022 - 01/2013
6	AcetylcholinesteraseIBA 04/2022 - 01/2008
6	Peptides (Polypeptides)IBA 09/2021 - 09/2010
4	Pharmaceutical PreparationsIBA 01/2022 - 01/2008
3	Biological ProductsIBA 12/2016 - 01/2010
2	Trace Elements (Biometals)IBA 04/2022 - 12/2016
2	ButyrylcholinesteraseIBA 04/2022 - 03/2018
2	6-chlorotacrineIBA 01/2022 - 03/2018
2	huprine YIBA 03/2018 - 04/2003
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 03/2018 - 01/2017
2	Tacrine (Cognex)FDA Link 03/2018 - 01/2012
2	Levetiracetam (Keppra)FDA LinkGeneric 01/2017 - 08/2015
1	Glycogen Synthase (Synthase I)IBA 04/2022
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 04/2022
1	Scopolamine (Hyoscine)FDA Link 04/2022
1	Epoxide HydrolasesIBA 01/2022
1	EnzymesIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 09/2018
1	Anti-Anxiety Agents (Anxiolytics)IBA 09/2018
1	PolyphenolsIBA 03/2018
1	quinolineIBA 03/2018
1	NitrogenIBA 03/2018
1	Pyridostigmine Bromide (Pyridostigmine)FDA LinkGeneric 03/2018
1	TriazolesIBA 03/2018
1	Cyanides (Isocyanides)IBA 01/2018
1	Antiparasitic Agents (Antiparasitics)IBA 01/2018
1	SaltsIBA 01/2018
1	Kainic Acid (Kainate)IBA 01/2018
1	huprine XIBA 01/2018
1	Donepezil (Aricept)FDA LinkGeneric 01/2017
1	Monoamine Oxidase (MAO)IBA 12/2016
1	CateninsIBA 12/2016
1	Serotonin (5 Hydroxytryptamine)IBA 12/2016
1	sigma Receptors (sigma Receptor)IBA 12/2016
1	Cholinesterases (Cholinesterase)IBA 12/2016
1	MelatoninIBA 12/2016
1	Nicotinamide PhosphoribosyltransferaseIBA 12/2016
1	Cholinergic Agents (Cholinergics)IBA 08/2015
1	Prion ProteinsIBA 04/2015
1	shogaolIBA 10/2014
1	rheinIBA 03/2014
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2013
1	Amyloid beta-PeptidesIBA 09/2010
1	3-hydroxybutanal (aldol)IBA 04/2006
1	PK 11195 (PK11195)IBA 04/2003

Therapy/Procedure

2	Oral Administration 01/2022 - 03/2015